A Message Framing Intervention for Increasing Parental Acceptance of Human Papillomavirus Vaccination

Learn more about:
Related Clinical Trial
CRTE7A2-01 TCR-T Cell for HPV-16 Positive Advanced Cervical, Anal, or Head and Neck Cancers Assessment of Patients’ Quality of Sexual Life After Anal Cancer Treatment Neoadjuvant PD-1 Blockade Combined With Chemotherapy Followed by Concurrent Immunoradiotherapy for Locally Advanced Anal Canal Squamous Carcinoma Patients Pencil Beam Proton Therapy for Recurrences in Anal Cancer Patients Previously Treated With Radiotherapy (DACG 5) Hyperthermia Enhanced Re-irradiation of Loco-regional Recurrent Tumors Detecting HPV DNA in Anal and Cervical Cancers ANCA II – Quality of Life and Functional Outcome in Patients With Anal Cancer RTX-321 Monotherapy in Patients With HPV 16+ Tumors Anal Injury Screening for High Risk HPV M7824 in Subjects With HPV Associated Malignancies Multimodal Monitoring of Radiotherapy Response in Squamous Cell Cancer Avastin/[18-F]-5-fluorouracil PET/CT Imaging Feasibility Project Assessment of Health Related Quality of Life in Patients Treated for Rectal Cancer Octreotide in Preventing or Reducing Diarrhea in Patients Receiving Chemoradiotherapy for Anal or Rectal Cancer Combination Immunotherapy in Subjects With Advanced HPV Associated Malignancies Function Following Laser for Anal Intraepithelial Neoplasia (FLAN) A Message Framing Intervention for Increasing Parental Acceptance of Human Papillomavirus Vaccination Anal Sphincter Prosthesis in Treating Patients Who Are Undergoing Surgery for Anal or Rectal Cancer Phase 2 Study of ADXS11-001 in Subjects With Carcinoma of the Anorectal Canal Pilot Study to Determine the Safety and Efficacy of Gardasil Against the Human Papilloma Virus (HPV) in HIV-infected Men Assessment of Symptom-Related Cytokines in Lung and Gastrointestinal (GI) Cancer Patients Identification of Predictive Factors for Physiological Hypermetabolism of the Anal Canal in 18F-FDG PET / CT Early Rectal Cancer: Endoscopic Submucosal Dissection or Transanal Endoscopic Microsurgery? Drainage Seton With Flap Versus EAS Preserving Seton in Treatment of Transsphincteric Anal Fistula HPV-SAVE: 9-Valent HPV Vaccine for High-Grade Anal Dysplasia Radiation Dosimetry Study Comparing 2 Different Patient Setups in Anal/Rectal Cancer Patients Comparing Two Types of Swabs in Collecting Cell Samples for Anal Pap Tests and Human Papillomavirus Tests in Men Who Have Sex With Men The HPV-SAVE Study Team: HPV Screening and Vaccine Evaluation in Men Who Have Sex With Men High-Resolution Anoscopy Perceived Discomfort Study Infrared Coagulator Ablation or Observation in Preventing Anal Cancer in HIV-Positive Patients With Anal Neoplasia Image Fusion PET, CT and 3D-ultrasound Examinations Hybrid Capture 2 Human Papiloma Virus (HPV) High-Risk Anal DNA Test ART: Anal Squamous Cell Carcinoma: Investigation of Functional Imaging During chemoRadioTherapy Anal HPV Tests in Screening for Cell Changes in the Anus in Patients With HIV Molecular Genetic and Pathological Studies of Anal Tumors Intensity-Modulated Radiation Therapy, Fluorouracil, and Mitomycin C in Treating Patients With Invasive Anal Cancer Capecitabine, Oxaliplatin, and Radiation Therapy in Treating Patients With Stage II or Stage III Anal Cancer QOL & Functional Outcomes After Combined Modality Tx for Anal CA: Comparison of Conventional vs IMRT A Study of mDCF in Combination or Not With Atezolizumab in Advanced Squamous Cell Anal Carcinoma Chemotherapy Plus Radiation Therapy in Treating Patients With Stage II or Stage III Anal Cancer Infrared Coagulation in Preventing Anal Cancer in Patients With HIV Who Have Anal Neoplasia Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Stage II or Stage III Anal Cancer Topical MTS-01 for Dermatitis During Radiation and Chemotherapy for Anal Cancer Radiochemotherapy +/- Durvalumab for Locally-advanced Anal Carcinoma. A Multicenter, Randomized, Phase II Trial of the German Anal Cancer Study Group Intrafractional Vaginal Dilation in Anal Cancer Patients Undergoing Pelvic Radiotherapy Screening for HIV-Associated Anal Cancer Combined Modality Therapy for Patients With With HIV and Stage I, Stage II, or Stage III Anal Cancer Cetuximab, Cisplatin, Fluorouracil, and Radiation Therapy in Treating Patients With Anal Cancer Study of IMRT Radiotherapy Concurrent Chemothrerapy for Anal Cancer A Prospective, Open-Label, Multi-center Comparison of Lymphoseek Identified Lymph Nodes and Clinically Identified Lymph Nodes of Subjects With Known Cancer of the Anus Prospective Observational Trial to Evaluate Quality of Life After Definitive Chemoradiation in Patients With Anal Cancer (LANACARE) Radiation Therapy Plus Fluorouracil With or Without Additional Chemotherapy in Treating Patients With Primary Anal Cancer Prospective Cohort on Quality of Sexual Life Among Men Who Have Sex With Men Treated for Anal Cancer With Concurrent Chemotherapy and Intensity-modulated Radiotherapy Trial To Test Safety And Efficacy Of Vaccination For Incurable HPV 16-Related Oropharyngeal, Cervical And Anal Cancer SGN-00101 in Preventing Anal Cancer in Patients With HIV Who Have Anal Neoplasia Anal Cancer Radiotherapy Study Radiation Therapy, Mitomycin, and Either Fluorouracil or Cisplatin in Treating Patients With Locally Advanced Anal Cancer Radiation Therapy, Cisplatin, Fluorouracil, and Cetuximab in Treating Patients With Locally Advanced Anal Cancer Individual Following in Anal Cancer With PET/CT Anal Cancer Screening Study The Prevent Anal Cancer Self-Swab Study Shared Decision Making With Anal Cancer Patients on Radiation Dose Predictive Value of FMISO-PET, FDG-PET-CT, DWI-MRI and DCE-MRI Scans for Patients With Anal Cancer Receiving Radiotherapy +/- Chemotherapy Quality of Life in Patients With Anal Cancer Functional Outcomes Following Anal Cancer Treatment Pembrolizumab in Refractory Metastatic Anal Cancer A Phase I/II Evaluation of ADXS11-001, Mitomycin, 5-fluorouracil (5-FU) and IMRT for Anal Cancer

Brief Title

A Message Framing Intervention for Increasing Parental Acceptance of Human Papillomavirus Vaccination

Official Title

A Message Framing Intervention for Increasing Parental Acceptance of Human Papillomavirus Vaccination

Brief Summary

      The goal of this study is to determine the effects of message framing (gain vs. loss) on
      African American parents' acceptance of the HPV vaccine and how such effects are moderated by
      parents' salient beliefs prior to message exposure. Participants are randomized into gain and
      loss conditions in which they view either gain-framed or loss-framed HPV vaccination
      messages. Key outcome variables include parents' attitudes and intentions toward vaccinating
      their children against HPV.
    

Detailed Description

      The goal of this study is to determine the effects of message framing (gain vs. loss) on
      African American parents' acceptance of the HPV vaccine and how such effects are moderated by
      parents' salient beliefs prior to message exposure. Participants recruited from local
      communities and online panels will complete a computer-assisted survey. In the survey
      participants will first answer questions related to their beliefs about HPV and the HPV
      vaccine (e.g., perceived susceptibility, perceived severity, perceived efficacy, perceived
      safety, etc.), as well as other background information. Then they will be presented with
      either a gain-framed or loss-framed human papillomavirus vaccination message. After the
      message exposure, they will answer questions related to their attitudes toward HPV
      vaccination, intentions to vaccinate their children, as well as other message response
      measures. Eligible participants are at least 21 years old, self-identify as African American,
      and are custodial parents or caretakers of at least one child ages 9-17 who has not initiated
      the HPV vaccine series.
    


Study Type

Interventional


Primary Outcome

Attitudes

Secondary Outcome

 Thoughts

Condition

Cervical Cancer

Intervention

Framed HPV vaccination messages

Study Arms / Comparison Groups

 Gain-framed messages
Description:  Participants in this arm receive gain-framed HPV vaccination messages.

Publications

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information


Recruitment Status

Behavioral

Estimated Enrollment

1170

Start Date

January 22, 2021

Completion Date

March 25, 2021

Primary Completion Date

March 25, 2021

Eligibility Criteria

        Inclusion Criteria:

          -  21 years or older

          -  Self-identify as African American

          -  Custodial parent or caretaker of at least one child ages 9-17 who has not initiated
             the HPV vaccine series

          -  Has access to Internet to complete the study

        Exclusion Criteria:

          -  Younger than 21 years

          -  Does not self-identify as African American

          -  Not a custodial parent or caretaker of at least one child ages 9-17 who has not
             initiated the HPV vaccine series

          -  Has no access to Internet to complete the study
      

Gender

All

Ages

21 Years - 99 Years

Accepts Healthy Volunteers

Accepts Healthy Volunteers

Contacts

Xiaoli Nan, , 

Location Countries

United States

Location Countries

United States

Administrative Informations


NCT ID

NCT03856437

Organization ID

1322177-1.1


Responsible Party

Sponsor

Study Sponsor

University of Maryland, College Park


Study Sponsor

Xiaoli Nan, Principal Investigator, University of Maryland, College Park


Verification Date

September 2021